Keryx Biopharmaceuticals Agrees to SPA for Phase III Perifosine Trial

Keryx Biopharmaceuticals, Inc. announced Wednesday that it has reached agreement with the U.S. Food and Drug Administration regarding a Special Protocol Assessment (SPA) on the design of a Phase 3 trial for its PI3K/Akt pathway inhibitor, KRX-0401 (perifosine), in patients with refractory metastatic colorectal cancer.
CNNMoney